Skip to main content
. 2018 Feb 1;2018(2):CD004879. doi: 10.1002/14651858.CD004879.pub5

aa Rudenko 1988.

Methods Apparently cluster‐randomised controlled trial of schoolchildren in the Kalinigrad, Russia in 1984‐85. The text seems to suggest that children were randomised by class. The children underwent daily clinical examination for 7 working days after inoculation: recorded temperature, complaints, inspection of skin, mucous from eyes, and condition of nasopharynx. Morbidity due to influenza and acute respiratory illness recorded during epidemic period (28 January to 3 March 1985).
 Antigenic activity determined by inhibition of haemagglutinin by "standard methods".
 Haematological and biochemical tests and analysis of urine carried out to evaluate safety of vaccine; samples taken before vaccination, 3 days after, and 1 month after each dose of vaccine.
 Haematological tests included full blood analysis, thrombocyte count, and lymphocyte index.
 Biochemical test included determination of C‐reactive protein, protein fraction, neuraminic acid, transaminase alanine‐aminotransferase, and urea.
 Antigenic activity carried out on subgroup of 240 children.
 Samples taken from 22 children who received vaccine and 18 who received placebo for re‐isolation of vaccine.
 Genetic stability of vaccine evaluated from swabs taken from nasopharynx after 1, 2, 3, 7, and 8 days. 3 criteria used: retention of antigenic specificity, temperature sensitive‐phenotype, localisation of temperature sensitive‐mutations in individual genes of re‐isolates.
 Statistical analysis of morbidity carried out using EVM employing the criteria of the "reliability of parameter differences of the binomial distribution".
 Influenza epidemic from 28 January to 3 March 1985, peak from 11 February to 17 February 1985. Epidemic caused by A(H3N2) (i.e. vaccine did not match circulating strain).
Participants
  • Children aged 3 to 15 years from nursery schools and schools

  • Children not inoculated against influenza in previous 3 years

Interventions Live influenza A(H1N1) vaccine given intranasally, 2 doses 28 to 30 days apart administered using Smirnov apparatus. An influenza epidemic took place from 28 January to 3 March 1985, peaking from 11 February to 17 February 1985. The epidemic was caused by A(H3N2) (i.e. vaccine did not match circulating strain).
Outcomes Serological
 Antigenic activity was determined by HAI, haematological tests included full blood analysis, and biochemical tests were also performed. 3 serum samples were taken from 240 children to test seroconversion. The basis for the sampling is not described.
Effectiveness
  • Morbidity due to influenza and acute respiratory illness during epidemic period (28 January to 3 March 1985)

  • Morbidity of other illnesses (excluding influenza and ARI) (data not extracted here)

  • Temperature reactions after 7 working days following inoculation

  • Seroconversion, HAI response to virus re‐isolates, temperature sensitivity of re‐isolates, temperature sensitive‐mutations (data not extracted for any of these outcomes)


Safety
 Reactogenicity was studied in a sample of 596 children after the first dose and in 164 children after the second dose. It is unclear on what basis the children in the samples were selected. The only outcome reported by arm was fever of various degrees, but no definition is given.
Funding Source Unclear
Notes The authors conclude that the vaccine did not affect morbidity because of mismatch between vaccine and circulating viruses. The vaccine also proved to be stable and not very reactogenic. No description of the vaccine content and unclear randomisation and attrition/sampling make interpretation of the results very difficult.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Insufficient description; cluster‐randomised trial
Allocation concealment (selection bias) High risk Not used
Blinding (performance bias and detection bias) 
 All outcomes Low risk Double‐blind
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk No description
Summary assessments High risk No description of the vaccine content and unclear randomisation and attrition/sampling make interpretation of the results very difficult.